Wyrnia si opakowaniem i naprawd czystym skadem
GLP-1 Receptor Agonists and Noncardiometabolic Outcomes
September 16, 2025: New Possible Lawsuit Option for People Who Experienced Ozempic-Related Vision Loss More medical studies are finding that people who take semaglutide drugs like Ozempic are at an increased risk of a type of blindness caused by NAION (non-arteritic anterior ischemic optic neuropathy)
A 2022 CADTH review 1 performed at the request of GPAC found: No studies evaluating the clinical utility of B 12 testing in people with suspected B 12 deficiency
Study author Sun H Kim, MD, MS, Associate Professor of Medicine in the Division of Endocrinology, Gerontology, and Metabolism at Stanford, summarized the findings to to Medical News Today , saying: We found that semaglutide compared to other weight loss medications, including another GLP-1 medication called dulaglutide, reduced risk of future fractures despite being associated with greater weight loss. Overall, semaglutide was linked to a bigger decrease in BMI
Recommendations often include taking oral semaglutide 30 minutes before your first food, beverage, or other oral medications of the day with no more than 4 ounces of plain water
